Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777769 | 0.96 | LMNA (0.35) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL5772394 | 0.95 | LMNA (0.37) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL5775964 | 0.91 | LMNA (0.37) | LMNAMAPTHTTKDM4EHTR2B | |
| SCHEMBL5778345 | 0.85 | LMNA (0.43) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL5777152 | 0.77 | LMNA (0.38) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL610883 | 0.70 | HTT (0.47) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL10768863 | 0.69 | KDM4E (0.45) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL24718227 | 0.68 | LMNA (0.46) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL30798594 | 0.68 | LMNA (0.46) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL5773407 | 0.67 | IKBKB (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1483257-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003076427-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | LMNA 945/4885MAPT 4800/4885HTT 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.